Welcome to our dedicated page for NANOVIRICIDES SEC filings (Ticker: NNVC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on NANOVIRICIDES's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into NANOVIRICIDES's regulatory disclosures and financial reporting.
NanoViricides, Inc. reported continued operating losses in its quarter and nine months ended March 31, 2026, while advancing its broad-spectrum antiviral NV‑387. Net loss was $1,989,333 for the quarter and $5,995,110 for the nine months, driven by $6,060,077 in operating expenses.
The company had cash and cash equivalents of $3,213,256 and total assets of $10,219,004, against total liabilities of $1,065,407 and an accumulated deficit of $154,836,971. Management states there is substantial doubt about its ability to continue as a going concern, as existing cash and a $3,000,000 related-party credit line are not expected to fund operations for 12 months.
To support liquidity, NanoViricides raised approximately $1,909,000 net via an at-the-market offering and $5,403,981 net through a Registered Direct Offering and concurrent private placement of warrants. As of May 14, 2026, there were about 21,647,000 common shares outstanding and 7,147,720 warrants outstanding.
NV‑387 completed a Phase I safety and tolerability trial in healthy subjects with no reported adverse events and was granted U.S. FDA Orphan Drug Designation on April 27, 2026 for the treatment of Measles, positioning it for potential orphan-focused development paths.
NanoViricides, Inc. reported a net loss of $4.0 million for the six months ended December 31, 2025, improving from a $5.2 million loss a year earlier as operating expenses declined. The company remains a clinical-stage antiviral developer with no revenue to date.
Cash and cash equivalents rose to $5.2 million from $1.6 million at June 30, 2025, driven by equity financings and a $6.0 million registered direct and private placement transaction, leaving stockholders’ equity at $11.1 million. However, management states that existing cash and an undrawn $3.0 million related-party credit line are not sufficient to fund planned operations for at least 12 months, and they conclude that substantial doubt exists about the company’s ability to continue as a going concern.
The lead broad-spectrum antiviral candidate NV-387 completed a Phase I safety and tolerability trial in healthy subjects with no reported adverse events, and the company is preparing Phase II studies, including for MPox and viral respiratory infections. NanoViricides is also pursuing orphan drug designations in the United States for NV-387 in Measles, MPox, and Smallpox while continuing development of its herpes-focused NV-HHV-1 program and maintaining extensive license arrangements with related-party TheraCour Pharma for multiple viral indications.
NanoViricides, Inc. is registering up to 7,142,858 shares of common stock for resale by a single selling stockholder. These shares are issuable upon exercise of Series A warrants for 3,571,429 shares at $1.75 per share and Series B warrants for 3,571,429 shares at $2.00 per share, all originally issued in a November 10, 2025 private placement. The company will not receive any proceeds from the resale of these shares, but could receive up to approximately $13.4 million in gross proceeds if all the warrants are exercised for cash.
NanoViricides is a clinical-stage company developing antiviral drugs based on its nanoviricides platform. Lead candidate NV-387 has completed a Phase Ia/Ib safety trial with no reportable adverse events and is being advanced toward Phase II trials for MPox and viral acute and severe-acute respiratory infections. As of mid‑December 2025, 21,568,429 shares of common stock were outstanding, with additional preferred shares and warrants reserved for future issuance.
NanoViricides, Inc. is registering up to 7,142,858 shares of common stock for resale by a selling stockholder, representing shares underlying Series A and Series B common stock purchase warrants.
The warrants, issued in a November 10, 2025 private placement, are exercisable at $1.75 and $2.00 per share and, if fully exercised for cash, could provide the company with approximately $13.4 million in gross proceeds, though the company will not receive any proceeds from resale of the shares themselves. The sole selling stockholder, Armistice Capital Master Fund, Ltd., beneficially owns 10,714,287 shares and is subject to a 4.99% beneficial ownership limitation on warrant exercises. As of November 10, 2025, NanoViricides had 21,568,429 common shares outstanding, and its most recent audited financial statements include an explanatory paragraph noting substantial doubt about the company's ability to continue as a going concern.
NanoViricides, Inc. (NNVC) reported the results of its 2025 Annual Meeting of Stockholders. A quorum was present, with 7,906,820 common shares and 838,025 Series A Convertible Preferred shares entitled to vote, representing approximately 61% of the company’s outstanding voting capital stock.
Stockholders re-elected Anil Diwan as a Class I Director, with 9,757,652 votes for, 173,096 against, and 48,971 abstentions. An advisory vote on the compensation of the named executive officers also passed, receiving 9,500,223 votes for, 420,374 against, and 59,122 abstentions. Stockholders further ratified the appointment of EisnerAmper, LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026, with 14,594,257 votes for, 194,416 against, and 60,051 abstentions.
NanoViricides, Inc. announced a capital raise combining a registered direct offering and a concurrent private placement. The company sold 1,970,000 registered shares at $1.68 and issued pre-funded warrants for 1,601,429 shares at $1.67999 with a $0.00001 exercise price, immediately exercisable. In the private placement, it issued Series A and Series B warrants for up to 3,571,429 shares each, exercisable six months after issuance at $1.75 (A, two-year term) and $2.00 (B, five-and-a-half-year term).
The transaction closed on November 12, 2025, generating approximately $6.0 million in gross proceeds before fees, to be used for working capital and general corporate purposes. A.G.P./Alliance Global Partners served as placement agent for a 7.0% cash fee, plus up to $60,000 in expenses and $15,000 in non-accountable expenses. The company agreed to a 90-day restriction on new equity issuances and filings, a 180-day prohibition on variable rate transactions, and 90-day lock-ups by directors and officers.
NanoViricides, Inc. filed its quarterly results for the period ended September 30, 2025, reporting a net loss of $1.79 million, improved from $3.13 million a year ago, as operating expenses fell to $1.80 million. Cash and cash equivalents were $1.13 million, with total assets of $8.36 million and current liabilities of $1.18 million.
Management stated that, despite raising $1.25 million via at‑the‑market sales during the quarter, and approximately $6 million in a registered direct offering completed on November 12, 2025 (plus additional ATM proceeds), there is substantial doubt about the Company’s ability to continue as a going concern. The Company also has access to a $3 million related‑party line of credit, undrawn at quarter‑end. Shares outstanding were 17,556,079 as of September 30, 2025; approximately 17,997,000 were outstanding as of November 14, 2025.
Operationally, the company highlighted progress for lead antiviral NV‑387, including completion of a Phase I safety trial and a final approval from DRC’s ACOREP in late October 2025 to start a Phase II MPox study, subject to conditions.
NanoViricides, Inc. launched a registered direct offering of 1,970,000 shares of common stock at $1.68 per share and pre-funded warrants to purchase up to 1,601,429 shares at $1.67999 per pre-funded warrant. This filing also covers 1,601,429 shares issuable upon exercise of those pre-funded warrants at an exercise price of $0.00001 per share, which are immediately exercisable.
The offering size is $6,000,000 in gross proceeds, with a 7% placement fee of $420,000; the company expects approximately $5,505,000 in net proceeds, earmarked for general corporate purposes including working capital, R&D and clinical trial expenditures. A.G.P./Alliance Global Partners is acting as exclusive placement agent on a reasonable best efforts basis.
In a concurrent private placement, the company is selling Series A warrants to purchase up to 3,571,429 shares at $1.75 (exercisable beginning six months for 18 months) and Series B warrants to purchase up to 3,571,429 shares at $2.00 (exercisable beginning six months for five years); these PIPE securities are not registered here. Shares outstanding were 18,006,532 immediately after the offering, as of November 10, 2025.